Coverage
-
July 15, 2016
The parties in a lawsuit challenging a pay-for-delay settlement between Teva Pharmaceuticals and GlaxoSmithKline over the latter’s epilepsy drug Lamictal are planning to settle the complaint, according to a letter filed Friday in New Jersey federal court.
4 other articles on this case.
View all »